NCT04552223View on ClinicalTrials.gov

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2026

Conditions
Metastatic Uveal Melanoma
Interventions
DRUG

Nivolumab

Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.

DRUG

Relatlimab

Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Jose Lutzky, MD

OTHER

NCT04552223 - Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter